このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

2019年12月27日 更新者:GlaxoSmithKline

Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants

This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2 months at the time of the first dose and previously uninfected with HRV. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

調査の概要

詳細な説明

Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV) vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo.

研究の種類

介入

入学 (実際)

765

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Aichi、日本、451-0052
        • GSK Investigational Site
      • Chiba、日本、275-8580
        • GSK Investigational Site
      • Fukuoka、日本、802-8533
        • GSK Investigational Site
      • Hiroshima、日本、720-8520
        • GSK Investigational Site
      • Hiroshima、日本、734-8530
        • GSK Investigational Site
      • Hiroshima、日本、737-0811
        • GSK Investigational Site
      • Hiroshima、日本、730-8518
        • GSK Investigational Site
      • Hiroshima、日本、730-8798
        • GSK Investigational Site
      • Hokkaido、日本、065-0033
        • GSK Investigational Site
      • Hokkaido、日本、003-0021
        • GSK Investigational Site
      • Kagawa、日本、765-8501
        • GSK Investigational Site
      • Kanagawa、日本、247-8533
        • GSK Investigational Site
      • Miyagi、日本、983-8520
        • GSK Investigational Site
      • Miyagi、日本、981-3203
        • GSK Investigational Site
      • Nagano、日本、386-8610
        • GSK Investigational Site
      • Nagasaki、日本、856-8562
        • GSK Investigational Site
      • Niigata、日本、957-8588
        • GSK Investigational Site
      • Okayama、日本、701-1192
        • GSK Investigational Site
      • Okayama、日本、701-0204
        • GSK Investigational Site
      • Osaka、日本、591-8025
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~3ヶ月 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Born between a gestation period of 36 and 42 weeks inclusive.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.
  • History of use of experimental rotavirus vaccine.
  • Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Previous confirmed occurrence of RV GE.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
  • A family history of congenital or hereditary immunodeficiency.
  • Acute disease at the time of enrolment.
  • Gastroenteritis within 7 days preceding the study vaccine administration.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Rotarix Group
Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
Two-dose oral vaccination.
プラセボコンパレーター:Placebo Group
Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
Two-dose oral administration.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type
時間枠:From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types
時間枠:From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From Dose 1 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From Dose 1 up to 2 years of age
Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration
時間枠:2 months after Dose 2
Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).
2 months after Dose 2
Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies
時間枠:2 months after Dose 2
Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.
2 months after Dose 2
Number of Subjects Reporting Solicited Symptoms
時間枠:During the 8-day follow-up period after each dose
Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.
During the 8-day follow-up period after each dose
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
時間枠:During the 31-day follow-up period after each dose
Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
During the 31-day follow-up period after each dose
Number of Subjects Reporting Serious Adverse Events (SAEs)
時間枠:Up to 2 years of age
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Up to 2 years of age

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2007年6月19日

一次修了 (実際)

2009年3月31日

研究の完了 (実際)

2009年11月21日

試験登録日

最初に提出

2007年5月29日

QC基準を満たした最初の提出物

2007年5月29日

最初の投稿 (見積もり)

2007年5月30日

学習記録の更新

投稿された最後の更新 (実際)

2020年1月2日

QC基準を満たした最後の更新が送信されました

2019年12月27日

最終確認日

2019年12月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 107625
  • 2015-001543-36 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD 共有時間枠

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD 共有アクセス基準

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

試験データ・資料

  1. インフォームド コンセント フォーム
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  2. 統計分析計画
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  3. 個人参加者データセット
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  4. 研究プロトコル
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  5. データセット仕様
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  6. 注釈付き症例報告書
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
  7. 臨床研究報告書
    情報識別子:107625
    情報コメント:For additional information about this study please refer to the GSK Clinical Study Register

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する